CONJUGATED ESTROGENS DELTA-(8,9) DHES DATA PROVIDE "NO DIRECT EVIDENCE" OF CONTRIBUTION TO PREMARIN, FDA REPORT FINDS; DATA ON RELEVANT DOSES NEEDED
The compound delta (8,9)-dehydroestrone sulfate has not been shown to have a direct contribution to Wyeth-Ayerst's Premarin in the data that has been submitted to FDA thus far, the agency concludes in a Nov. 1 report on the "Preliminary Analysis of Scientific Data on the Composition of Conjugated Estrogens."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth